Results 21 to 30 of about 17,845 (225)

Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations

AIDS (London)
Background: Dolutegravir is widely used in different dual and triple antiretroviral regimens. Here, we sought to investigate the effect of the companion antiretroviral drug(s) on dolutegravir plasma trough concentrations in persons with HIV, with a focus
Giacomelli, Andrea, Cattaneo, Dario, Pagano, Simone, Gervasoni, Cristina, Colombo, Martina Laura, Gori, Andrea   +5 more
core   +2 more sources

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Metabolites, 2022
Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir
Jessica Cusato, Alberto Borghetti, Elisabetta Teti, Maurizio Milesi, Maria Cristina Tettoni, Stefano Bonora, Mattia Trunfio, Antonio D’Avolio, Mirko Compagno, Simona Di Giambenedetto, Giovanni Di Perri, Andrea Calcagno   +11 more
doaj   +1 more source

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]

Wellcome Open Research, 2021
Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs).
Rulan Griesel, Andrew Hill, Graeme Meintjes, Gary Maartens   +3 more
doaj   +1 more source

Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda

BMC Public Health, 2020
Background Despite concerns about dolutegravir use in pregnancy, most low- and middle-income countries are accelerating the introduction of dolutegravir-based regimens into national antiretroviral treatment programmes.
Yussif Alhassan, Adelline Twimukye, Thoko Malaba, Catherine Orrell, Landon Myer, Catriona Waitt, Mohammed Lamorde, Andrew Kambugu, Helen Reynolds, Saye Khoo, Miriam Taegtmeyer   +10 more
doaj   +1 more source

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety

Journal of Global Antimicrobial Resistance, 2020
Objectives: In the HIV-1-positive population, a paradigm shift from three-drug regimens (3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment is beginning to take place, supported virologically by the availability of ...
Valeria Cento, Carlo Federico Perno
doaj   +1 more source

The risk of hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study

The Lancet Global Health, 2022
Background: Emerging evidence suggests a possible association between hyperglycaemia and use of dolutegravir, a preferred first-line antiretroviral agent in sub-Saharan Africa.
Daphine Namara, MBChB, Jeremy I Schwartz, MD, Andrew K Tusubira, MPH, Willi McFarland, ProfMD, Caroline Birungi, MMed, Fred C Semitala, MMed, Martin Muddu, MMed   +6 more
doaj   +1 more source

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Viruses, 2023
Background: Since limited data are available, we aimed to compare the efficacy and durability of dolutegravir and darunavir in advanced naïve patients. Methods: Retrospective multicenter study including AIDS- or late-presenting (def.
Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello, Simona Di Giambenedetto   +15 more
doaj   +1 more source

Six-Step Gram Scale Synthesis of the HIV Integrase Inhibitor Dolutegravir Sodium

, 2021
A short and practical synthesis for preparing the active pharmaceutical ingredient dolutegravir sodium was investigated. The convergent strategy developed herein starts from 3-(R)-amino-1- butanol and builds up the BC ring system in 76% isolated yield ...
Sebastian, Seitel, Dorota, Ferenc, Jule-Phillip, Dietz, B. Frank, Gupton, Jan, Brauer, Tobias, Lucas, Jonathan, Groß, Till, Opatz   +7 more
core   +1 more source

Adverse events of raltegravir and dolutegravir [PDF]

, 2017
OBJECTIVE To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. DESIGN Prospective cohort study.
Swiss HIV Cohort Study, Battegay, Manuel, Erb, Stefan, Enos Bernasconi, Furrer, Hansjakob, Hansjakob Furrer, Alexandra Calmy, Stefan Erb, Luigia Elzi, Manuel Battegay, Elzi, Luigia, Huldrych Günthard, Pietro Vernazza, Vernazza, Pietro, Günthard, Huldrych, Calmy, Alexandra, Cavassini, Matthias, Bernasconi, Enos, Matthias Cavassini   +18 more
core   +1 more source

Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa. [PDF]

, 2022
INTRODUCTION Dolutegravir is being scaled up globally as part of antiretroviral therapy (ART), but for people with HIV and tuberculosis co-infection, its use is complicated by a drug-drug interaction with rifampicin requiring an additional daily dose ...
Cleophas Chimbetete, Tiendrebeogo, Thierry, Matthew L. Romo, Patricia Lelo, Lelo, Patricia, N. Sarita Shah, Wools-Kaloustian, Kara K, Christelle Twizere, Muhairwe, Josephine A., Sekaggya‐Wiltshire, Christine, Thierry Tiendrebeogo, De Waal, Reneé, Mahambou-Nsondé, Dominique, Sekaggya-Wiltshire, Christine, Christine Sekaggya‐Wiltshire, Brazier, Ellen, Romo, Matthew L, Muyindike, Winnie R, Shah, N Sarita, Nash, Denis, Gad Murenzi, Rafael, Idiovino, Muhairwe, Josephine A, Fenner, Lukas, Denis Nash, Yotebieng, Marcel, Ezechi, Oliver C, Lameck Diero, Wools‐Kaloustian, Kara K., Shah, N. Sarita, Cordelia Kunzekwenyika, Romo, Matthew L., Dzudie, Anastase, Dominique Mahambou‐Nsondé, Josephine A. Muhairwe, Reneé De Waal, Idiovino Rafael, Diero, Lameck, Lukas Fenner, Twizere, Christelle, Mahambou‐Nsondé, Dominique, Ellen Brazier, Kunzekwenyika, Cordelia, Chimbetete, Cleophas, Kara K. Wools‐Kaloustian, Winnie R. Muyindike, Ezechi, Oliver C., Wools-Kaloustian, Kara K., International epidemiology Databases to Evaluate AIDS (IeDEA), Muyindike, Winnie R., Oliver C. Ezechi, Marcel Yotebieng, Murenzi, Gad, Anastase Dzudie   +53 more
core   +1 more source